Truist Financial analyst Terry Tillman maintained a Hold rating on Shopify (SHOP – Research Report) today. The company’s shares closed last ...

Truist Financial analyst Joon Lee maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today. The company’s shares closed ...

Truist Financial Corp lifted its holdings in shares of Curtiss-Wright Co. (NYSE:CW – Free Report) by 6.2% during the 4th ...

Truist Financial Corp boosted its holdings in Globant S.A. (NYSE:GLOB – Free Report) by 2.6% in the 4th quarter, according to ...

The legendary investor expressed his inclination for equities even after selling large chunks of Berkshire Hathaway's ...

The commission voted 6-0 to recommend passage of Ordinance 2025-0074, which would allow for an exception to Downtown zoning ...

This was the stock's third consecutive day of gains.

The trial data, which was reported on February 18, 2025, also suggested potential cardiac benefits from the therapy. The company mentioned that SGT-003 has been well-tolerated with no serious adverse ...

In 2024, financial stocks have led the market, delivering one of the strongest performances among all sectors.

Looking for dividend income? Explore these high-paying dividend stocks from the S&P 500 for potential returns in 2025.

We are maintaining our fair value estimate for Truist Financial at $47 per share. We value the firm at roughly 1.6 times tangible book value as of the end of 2024.